Successful Launch of Mechanism of Action Based Pipeline Reports by DelveInsight

DelveInsight's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Get the idea what other companies are doing with the targets you are interested in and what their progress and strategize to get the best out of it with MOA Pipeline Reports.



Dwarka, Delhi, India., July 24, 2014 - (PressReleasePoint) -After a successful launch of Drug and Indication Reports under Pharm Delve Series, DelveInsight has come up with a Pipeline Reports under brand name Pharm Insights covering 700+ Mechanism of Action reports.

Mechanism of Action Based Reports is one of a kind report which will provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). This report provides information on the therapeutic development based on the certain MOA dealing with the target, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

“In this highly competitive world, everybody wants to understand the pace of their competitors. Mechanism of Action based reports is the key for them” said Ms Mridhu Verma, Analyst at DelveInsight.

These reports can be available through leading resellers such as Report Linker’s, Report Buyer’s and Report stack or you can directly contact at info@delveinsight.com.

For more information visit: http://www.delveinsight.com/
 

Press Contact:
DelveInsight Team
212, 2nd floor,Vardhaman DeeCee Plaza,Sector-11, Plot-6, Dwarka. New Delhi-110075
+91-11-4568 9769
http://www.delveinsight.com
****@d**v**n**g**.com
Email partially hidden to block spam. Please use the contact form here.
Contact DelveInsight Team
Email the contact person for this press release. Do not send spam or irrelevant message.
12 + 5 =


Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

9 + 11 =